Alan Cox, MD
Gastroenterology · Louisville, KYNPI 1154305696
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 863 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 28.7% of the total. 2025 is the largest year on record at $2,581, 2.1 times the $1,220 reported in 2019.
Across 863 payments — averaging $15.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Pfizer$790
- Sanofi$548
- plus $4K from 28 others
What the payments were for
- Food & beverage$13,054100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 285 | $3,741 |
| Takeda Pharmaceuticals U.S.A., Inc. | 116 | $1,678 |
| Johnson & Johnson | 112 | $1,610 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 74 | $1,064 |
| Pfizer | 57 | $790 |
| Sanofi | 26 | $548 |
| Ardelyx, Inc. | 31 | $521 |
| Bristol Myers Squibb | 36 | $483 |
| Ironwood Pharmaceuticals, Inc | 22 | $355 |
| Regeneron Healthcare Solutions, Inc. | 12 | $290 |
| Madrigal Pharmaceuticals | 9 | $289 |
| QOL Medical, LLC | 11 | $267 |
| Phathom Pharmaceuticals, Inc. | 18 | $267 |
| E.r. Squibb & Sons, L.L.C. | 2 | $185 |
| Ferring Pharmaceuticals Inc. | 6 | $124 |
| Gilead | 5 | $93 |
| Intercept Pharmaceuticals, Inc. | 5 | $89 |
| Braintree Laboratories, Inc. | 5 | $88 |
| Boston Scientific | 4 | $83 |
| Merck | 4 | $81 |
| Aimmune Therapeutics, Inc. | 3 | $81 |
| UCB, Inc. | 5 | $73 |
| Lilly USA, LLC | 3 | $47 |
| Amgen | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 1 | $28 |
| Albireo Pharma, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| Redhill Biopharma Inc. | 1 | $16 |
| Shionogi Inc | 1 | $14 |
| Axonics, Inc. | 1 | $14 |
| Sandoz | 1 | $13 |
| Medtronic | 1 | $13 |
| Organon | 1 | $8 |
How this compares
$13,054 in reported general payments places this provider in the 85th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 16 | $439,483 |
| RemicadeInfliximab | 11 | $127,647 |
| CreonLipase/Protease/Amylase | 25 | $76,137 |
| Humira PenAdalimumab | 11 | $74,927 |
| RezdiffraResmetirom | 12 | $46,335 |
| LinzessLinaclotide | 31 | $36,090 |
| RelistorMethylnaltrexone Bromide | 19 | $24,123 |
| Mesalamine | 26 | $22,340 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 234 | $15,886 |
| Dexlansoprazole DrDexlansoprazole | 40 | $11,009 |
| VoqueznaVonoprazan Fumarate | 15 | $9,113 |
| Ursodiol | 31 | $6,442 |
| Balsalazide Disodium | 27 | $6,264 |
| Mesalamine DrMesalamine | 17 | $5,353 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 269 | $4,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Remicade | $1,610 | $567,13027 claims |
| AbbVieCreon, Linzess | $3,741 | $112,22856 claims |
| Madrigal PharmaceuticalsRezdiffra | $289 | $46,33512 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $1,064 | $24,12319 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $267 | $9,11315 claims |
| SandozLansoprazole | $13 | $1,22920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 207 gastroenterology providers in Kentucky.
Other gastroenterology in Louisville
- Gerald DrydenLouisville$2.1M
- Matthew CaveLouisville$340K
- Michael KreaseLouisville$322K
- Sunana SohiLouisville$220K
- Jeffrey TuvlinLouisville$202K
- Stephen McClaveLouisville$124K
- Ashutosh BarveLouisville$43K
- Thomas AbellLouisville$36K
- Nanlong LiuLouisville$31K
- Craig McClainLouisville$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.